Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philogen

- PMLiVE

Boehringer Ingelheim’s John Pugh set for move to Accenture

Will take up London-based role in theconsultants' digital department

- PMLiVE

Amgen’s Blincyto effective in broader leukaemia population

Could lead to further licences for the $178,000 blood cancer treatment

National Institute for Health and Care Excellence NICE logo

NICE opens consultation on Gilead’s leukaemia drug

Comes after the Institute rejects the treatment in new draft guidance

Boehringer Ingelheim headquarters

Boehringer teams up with Eureka on intracellular cancer targets

Alliance will use Eureka technology to identify antibodies recognising relevant proteins

- PMLiVE

Boehringer drug approved in EU for rare lung disease

Nintedanib is already available as cancer treatment

- PMLiVE

Boehringer partners with US universities

Will work with Yale and Vanderbilt on cancer projects

- PMLiVE

Amgen sets premium price for Blincyto

Leukaemia drug becomes one of the most expensive pharma products on the market

- PMLiVE

NICE recommends Pradaxa in blood clot indication

Boehringer drug backed to treat and prevent deep vein thrombosis and pulmonary embolism

- PMLiVE

ASH: Pradaxa antidote effective in key patient groups

Boehringer posts positive data on use of idarucizumab in elderly and people with kidney impairment

EU flag

Boehringer’s Vargatef approved in the EU for lung cancer

Marks company’s second oncology drug to hit market

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

NICE backs GSK drug for leukaemia

Arzerra on course for NHS use in blood cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links